-
Fixed-duration ibrutinib–venetoclax with MRD-guided ibrutinib–obinutuzumab intensification in first-line chronic lymphocytic leukaemia (HOVON 158/NEXT STEP): primary analysis of a multicentre, open-label, phase 2 trial
Kater, A. P., Kersting, S., Dubois, J. M., van der Holt, B., da Cunha-Bang, C., te Raa, D., Idink, C., de Boer, F., Droogendijk, J., de Heer, K., van der Burg, L., Nijziel, M. R., Tick, L., Levenga, H., Silbermann, M., Ludwig, I., Beeker, A., Bellido, M., Dobber, J. A. & Evers, L. M. & 9 others, , 1 Dec 2025, In: The Lancet Haematology. 12, 12, p. e935-e945Research output: Contribution to Journal › Article › Academic › peer-review
-
Uncovering the ultra-frail: A distinct subgroup in non-transplant eligible newly diagnosed patients with multiple myeloma, with an inferior clinical outcome
Groen, K., Smits, F., Nasserinejad, K., Levin, M.-D., Regelink, J. C., Timmers, G.-J., de Waal, E. G. M., Westerman, M., Velders, G. A., de Heer, K., Leys, R. B. L., van Kampen, R. J. W., Stege, C. A. M., Seefat, M. R., Nijhof, I. S., van der Spek, E., Klein, S. K., van de Donk, N. W. C. J., Ypma, P. F. & Zweegman, S., 1 Dec 2025, In: HemaSphere. 9, 12, e70268.Research output: Contribution to Journal › Comment / Letter to the editor › Academic
-
Real-world efficacy and safety of immunochemotherapy in cold agglutinin-mediated autoimmune haemolytic anaemia
Mulder, F. V. M., Becking, A.-M. L., Bernelot Moens, S. J., Jalink, M., Evers, D., Te Boome, L., Breedijk, A., Droogendijk, J., van der Griend, R., de Heer, K., Mäkelburg, A. B. U., Mandigers, C. M. P. W., Nieuwenhuizen, L., Oostvogels, R., Pruijt, J. F. M. H., Regelink, J., Rozenberg, J., Strobbe, L., van der Valk, F. M. & Lissenberg-Witte, B. I. & 1 others, , Dec 2025, In: British Journal of Haematology. 207, 6, p. 2653-2658 6 p.Research output: Contribution to Journal › Article › Academic › peer-review
- All publications
